Journal of Clinical Immunology

, Volume 32, Issue 4, pp 802-808

First online:

Type17 T-cells in Central Nervous System Autoimmunity and Tumors

  • Hideho OkadaAffiliated withDepartment of Neurological Surgery, University of Pittsburgh School of MedicineBrain Tumor Program, University of Pittsburgh Cancer InstituteNeurological Surgery, Surgery and Immunology, Clinical and Translational Science Institute, University of Pittsburgh School of Medicine Email author 
  • , Samia J. KhouryAffiliated withCenter for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical SchoolAmerican University of Beirut

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Interleukin-17 (IL-17) producing Type17 T-cells, specifically T-helper (Th)17 cells reactive to central nervous system (CNS) autoantigens, manifest a higher migratory capability to the CNS parenchyma compared with other T-cell subpopulations due to their ability to penetrate the blood brain barrier (BBB). In the field of cancer immunotherapy, there are now a number of cell therapy approaches including early studies using T-cells transduced with chimeric antigen receptors in hematologic malignancy, suggesting that the use of T-cells or genetically modified T-cells could have a significant role in effective cancer therapy. However, the successful application of this strategy in solid tumors, such as CNS tumors, requires careful consideration of critical factors to improve the tumor-homing of T-cells. The current review is dedicated to discuss recent findings on the role of Type17 T-cells in CNS autoimmunity and cancer. The insight gained from these findings may lead to the development of novel therapeutic and prophylactic strategies for CNS autoimmunity and tumors.


Th17 IL-17 autoimmunity central nervous system multiple sclerosis gliomas adoptive transfer therapy